Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment

Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment

Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In additi...

Full description

Bibliographic Details
Main Authors: Luis Sarabia De Ardanaz, Jose M. Andreu-Ubero, Miriam Navidad-Fuentes, Miguel Ángel Ferrer-González, Victor Ruíz del Valle, Inmaculada Salcedo-Bellido, Rocío Barrios-Rodríguez, Rafael Cáliz-Cáliz, Pilar Requena
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Pharmacology
Subjects:
COVID-19
immunosupression
tocilizumab
mortality
risk factor
platelet
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.620187/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.620187/full

Similar Items